Visceral adiposity and inflammatory bowel disease

Rowan, Catherine; McManus, J. P. A.; Boland, Karen; O’Toole, Aoibhlinn

doi:10.1007/s00384-021-03968-w

Cited by 32 publications

(30 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, although BMI is used widely, it does have limitations, including the inability to differentiate visceral adiposity from lean body mass. Visceral adiposity may be a more reflective indicator that could potentially play a role in evaluating the response to biologics in IBD, although current data are conflicting [ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of obesity on vedolizumab response in inflammatory bowel disease

Levine¹

2022

aog

View full text Add to dashboard Cite

Background Vedolizumab is used in inflammatory bowel disease (IBD), administered as a non-weight-based fixed dose. A higher body mass index (BMI) is associated with lower serum vedolizumab levels, but it is unclear whether it is associated with an unfavorable response to vedolizumab. We examined the relationship between BMI and the need for dose escalation, and the overall response to vedolizumab in IBD patients. Methods This was a single-center, retrospective study of IBD patients who received vedolizumab between 1 st July 2014 and 1 st September 2020. The primary outcome was need for vedolizumab dose escalation or discontinuation. Secondary outcomes were steroid-free clinical remission (SFCR), endoscopic remission, and normal serum C-reactive protein (CRP). Outcomes were compared between patients with BMI <30 kg/m 2 (non-obese) or ≥30 kg/m >2 (obese). Results 190 patients were included, with a median follow-up time of 21 months. Median age was 37 years, 50.5% were male, and median BMI was 24.8 kg/m 2 (75.3% of patients had BMI <30 kg/m 2 ). Vedolizumab was dose-escalated in 48.9% of the obese group vs. 42% of the non-obese group (P=0.4). Vedolizumab was discontinued in 31.9% of the obese group vs. 53.2% of the non-obese group (P=0.01). The rate of CRP normalization was significantly lower in the obese group (46.2% vs. 66%, P=0.03). SFCR and endoscopic remission rates were not significantly different between the groups. Conclusions Obesity was not associated with higher rates of vedolizumab dose escalation. However, it was associated with lower rates of vedolizumab discontinuation and CRP normalization, but not SFCR or endoscopic remission.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of obesity on vedolizumab response in inflammatory bowel disease

Levine¹

2022

aog

View full text Add to dashboard Cite

show abstract

“…Finally, we also need to consider the fact that VAT can exert a negative impact on bone quality through the promotion of a more severe evolution of IBD. The hypertrophy of mesenteric adipose tissue in CD has long been recognized and is positively correlated with a more severe prognosis [58], while a higher VAT/SAT ratio seems to be correlated to a more aggressive phenotype [59,60].…”

Section: Discussionmentioning

confidence: 99%

Body Composition as a Modulator of Bone Health Changes in Patients with Inflammatory Bowel Disease

Soare

Sîrbu

Popa

et al. 2022

Life

View full text Add to dashboard Cite

Background: Bone impairment of multifactorial etiology is a common feature in inflammatory bowel disease (IBD). Body composition parameters, which might be selectively modified in these patients, are important determinants of bone strength. Our aim was to investigate the relationship between components of body composition and bone parameters in IBD patients. Methods: This is a cross-sectional, retrospective study including 80 IBD patients (43 women, 37 men). Lumbar spine (LS), femoral neck (FN) and whole body DXA scans were performed to analyze regional bone mineral density (BMD), as well as body composition, including appendicular skeletal muscle mass index (ASMI), total and visceral fat mass (VAT). Trabecular bone score (TBS) was assessed using iNsight Software. Results: Twenty (25%) IBD patients had inadequate LS-BMD z scores (<=−2DS). Lean mass (LM) was a significant determinant of LS-BMD, after adjusting for age, gender, BMI and fat mass (p < 0.01), while fat mass% remained associated with FN-BMD (p < 0.01). TBS correlated positively with BMI (r = 0.24, p < 0.05), LS-BMD (r = 0.56, p < 0.001), ASMI (r = 0.34, p < 0.001) and negatively with VAT/total fat% (r = −0.27, p < 0.05). Multivariate analysis showed that ASMI, LS-BMD (positively) and VAT/total fat% (negatively) were independently associated with TBS. Conclusions: In IBD patients, skeletal muscle mass and fat percentage and distribution are important factors associated with bone health.

show abstract

“…A retrospective study conducted by Rowan et al demonstrated increased visceral adiposity in CD patients but not in UC [169]. Magro et al showed increased visceral fat in CD patients compared with controls.…”

Section: Obesity In the Pathogenesis Of Ibdmentioning

confidence: 97%

“…In obesity, expansion of all adipose depots takes place. Visceral adiposity is considered a risk factor for metabolic syndromes and many inflammatory diseases including GI diseases [167][168][169].…”

Section: Obesity In the Pathogenesis Of Ibdmentioning

confidence: 99%

“…A study conducted by Yang et al showed that mesenteric adipose tissue (MAT) collected from obese diabetic subjects had high gene expression of leptin, PPAR-γ, fatty acid translocase (FAT/CD36), and 11β hydroxysteroid hydrogenase (HSD) suggesting that alteration in the mesenteric depot may play a role in the development of metabolic syndrome [181]. Others reported that the term VAT is used interchangeably with MAT as visceral adiposity is the accumulation of fat in the intra-abdominal region [169]. Therefore, in obesity, an increase in visceral fat may also mean an increase in mesenteric fat.…”

Section: Role Of Adipose Tissuementioning

confidence: 99%

See 1 more Smart Citation

The Role of Gut Microbiota and Metabolites in Obesity-Associated Chronic Gastrointestinal Disorders

et al. 2022

View full text Add to dashboard Cite

The gut microbiota is a complex community of microorganisms that has become a new focus of attention due to its association with numerous human diseases. Research over the last few decades has shown that the gut microbiota plays a considerable role in regulating intestinal homeostasis, and disruption to the microbial community has been linked to chronic disease conditions such as inflammatory bowel disease (IBD), colorectal cancer (CRC), and obesity. Obesity has become a global pandemic, and its prevalence is increasing worldwide mostly in Western countries due to a sedentary lifestyle and consumption of high-fat/high-sugar diets. Obesity-mediated gut microbiota alterations have been associated with the development of IBD and IBD-induced CRC. This review highlights how obesity-associated dysbiosis can lead to the pathogenesis of IBD and CRC with a special focus on mechanisms of altered absorption of short-chain fatty acids (SCFAs)

show abstract

Visceral adiposity and inflammatory bowel disease

Cited by 32 publications

References 43 publications

Effect of obesity on vedolizumab response in inflammatory bowel disease

Effect of obesity on vedolizumab response in inflammatory bowel disease

Body Composition as a Modulator of Bone Health Changes in Patients with Inflammatory Bowel Disease

The Role of Gut Microbiota and Metabolites in Obesity-Associated Chronic Gastrointestinal Disorders

Contact Info

Product

Resources

About